Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Evaluating venetoclax with BR for the treatment of relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Aug 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of venetoclax (Venclexta) plus BR (bendamustine, rituximab) in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was tolerated and showed promising effectiveness in these patients. Some...

Read More

Comparing targeted therapy to chemotherapy for patients with advanced NSCLC

Posted by on Aug 8, 2018 in Lung cancer | 0 comments

In a nutshell This trial compared the effectiveness of alectinib (Alecensa) against chemotherapy for treating patients with ALK-positive non-small-cell lung cancer that have progressed passed previous targeted therapy. The authors determined that alectinib was more effective than chemotherapy at treating this subgroup of patients. Some background Lung...

Read More

Brentuximab vedotin: a study of its safety for unresponsive Hodgkin lymphoma.

Posted by on Jul 3, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to analyse the side effects associated with brentuximab vedotin (BV; Adcetris) treatment for patients with Hodgkin lymphoma (HL) who had undergone stem cell transplantation (SCT) that is now unresponsive to treatment. The main side effects identified included nerve damage, infections and low white blood cell...

Read More

Is busulfan a useful drug to improve successful transplantation in the treatment of acute leukemia?

Posted by on Jun 26, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effect of using busulfan to delete blood cancer cells from the system before replacing them with normal cells in the treatment of leukaemia. The study found that busulfan therapy was effective in removing blood cancer cells before replacement, in the treatment of high-risk acute leukaemia. Some background Acute...

Read More

What are the effects of treatment with brentuximab vedotin plus bendamustine on unresponsive HL?

Posted by on Jun 19, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effects of pre-stem cell transplantation (pre-SCT) treatment with brentuximab vedotin (Adcetris) and bendamustine (Treanda) on patients with relapsing/refractory Hodgkin's Lymphoma (HL) following transplant. The main finding was that the drug combination was effective as a pre-SCT therapy. Some...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT in mantle cell lymphoma?

Posted by on May 31, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...

Read More